Ugwuanyi raised the concern while speaking about kidney disease prevention and the challenges of providing specialised healthcare in Nigeria. He urged Nigerians to take routine health checks seriously, particularly blood pressure and blood sugar tests, rather than waiting until symptoms become severe.
However, the monthly estimate has not been independently established through a comprehensive national reporting system. Nigeria also lacks a single national registry that provides a definitive picture of the country's chronic kidney disease burden.
Professor Fatiu Arogundade, Vice-Chancellor of the Federal University of Medicine and Medical Sciences, Abeokuta, has separately estimated that about 25.4 million Nigerian adults could be living with chronic kidney disease. His estimate was based on research findings and population projections, rather than a nationwide count of diagnosed patients.
Hypertension and diabetes remain important risk factors for kidney damage. When poorly controlled over time, both conditions can affect the blood vessels and filtering structures responsible for maintaining normal kidney function.
The World Health Organisation identifies high blood pressure and diabetes as major conditions associated with chronic kidney disease. It recommends early detection, particularly among people living with these conditions, through appropriate kidney function and urine tests.
Ugwuanyi also warned against the indiscriminate use of painkillers, particularly non-steroidal anti-inflammatory drugs such as ibuprofen, indomethacin and naproxen. These medicines can affect kidney function, especially when misused or taken by people with existing kidney problems.
The wider concern also includes self-medication and the inappropriate use of antibiotics. Health professionals have repeatedly cautioned that medicines should be taken according to appropriate medical advice, as misuse can create additional health risks.
Beyond prevention, the cost of managing advanced kidney disease remains a major challenge for many Nigerian households. Patients with kidney failure may require dialysis or a transplant, depending on their medical condition and specialist assessment.
The financial burden can be substantial, particularly for patients who require repeated dialysis sessions. A report published by The Guardian in March 2026 highlighted the pressure on patients and families, with dialysis costs reported at between ₦50,000 and ₦80,000 per session in some facilities.
The Federal Government introduced a dialysis subsidy programme in 2025, reducing the cost of a session to ₦12,000 in participating federal tertiary hospitals. However, the intervention was initially being implemented in a limited number of facilities, meaning access was not universal.
The National Health Insurance Authority also lists haemodialysis among its covered services, but its published benefit information limits coverage to six sessions annually. This highlights the gap between available insurance support and the needs of patients requiring regular treatment.
The challenge has renewed calls for wider health insurance coverage, more affordable essential medicines, investment in kidney treatment facilities and stronger primary healthcare services.
Regular screening for high blood pressure and diabetes, improved access to medical consultations and public education on responsible medicine use are among the measures that can help reduce preventable kidney complications.
The World Health Organisation recommends integrating kidney health into primary healthcare, with appropriate testing and early management for people at increased risk. It also emphasises the importance of equitable access to essential treatment, including dialysis and transplantation where required.
Nigeria's response will therefore require more than public awareness campaigns. Stronger preventive services, reliable health financing and wider access to specialised treatment will be important in addressing the country's growing kidney disease burden.
Reporting by TalkNaijaMedia
Reader Comments (0)
No comments yet. Be the first to share your perspective on this report.